The Analyst(@MMatters22596):$NVO Down more than 4% pre-market after its Capital Markets Day. Investors are mainly reacting to slower Wegovy growth and increasing competition from $LLY. But $NVO remains an obvious long-term holding for me: - 5+ multi-blockbusters targeted by 2030 - 10x higher capacity for oral GLP-1 obesity patients - 60M+ patients targeted globally by 2030 - Oral obesity gamechanger: $NVO still leads $LLY in adoption The broader negative sentiment also supports my short-term bearish outlook. I still expect a final bottom somewhere between $32 and $16. After that, I expect a sustained recovery toward $64 and eventually $81+ over the mid to long term.

2026.09.21 12:41

$NVO Down more than 4% pre-market after its Capital Markets Day. Investors are mainly reacting to slower Wegovy growth and increasing competition from $LLY. But $NVO remains an obvious long-term holding for me: - 5+ multi-blockbusters targeted by 2030 - 10x higher capacity for oral GLP-1 obesity patients - 60M+ patients targeted globally by 2030 - Oral obesity gamechanger: $NVO still leads $LLY in adoption The broader negative sentiment also supports my short-term bearish outlook. I still expect a final bottom somewhere between $32 and $16. After that, I expect a sustained recovery toward $64 and eventually $81+ over the mid to long term.